Mark Sutherland
Impact in
- Immunology top 10%
- Toxin Mechanisms and Immunotoxins
- Biochemistry top 5%
- Eicosanoids and Hypertension Pharmacology
Papers in
- Immunology 11
- Toxin Mechanisms and Immunotoxins 11
-
- Eicosanoids and Hypertension Pharmacology 5
- Co-authors
- Hendrik Fuchs (14 shared papers)Christopher Bachran (12 shared papers)Iring Heisler (7 shared papers)Diana Bachran (7 shared papers)Laurence H. Patterson (10 shared papers)Steven D. Shnyder (9 shared papers)Matthias F. Melzig (4 shared papers)Tankred SCHEWE (4 shared papers)
- Journals
- FEBS Letters (2 papers)PLoS ONE (2 papers)International Journal of Cancer (2 papers)Journal of Controlled Release (2 papers)Life Sciences (2 papers)
- Partner nations
- GermanyUnited KingdomUnited Arab Emirates
In The Last Decade
Mark Sutherland
35 papers receiving 966 citations
Peers
Comparison fields: 5 of 79
- Immunology 239
- Biochemistry 64
- Pharmacology 82
- Drug Discovery 2
- Molecular Biology 350
Countries citing papers authored by Mark Sutherland
This map shows the geographic impact of Mark Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sutherland more than expected).
Fields of papers citing papers by Mark Sutherland
This network shows the impact of papers produced by Mark Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sutherland. The network helps show where Mark Sutherland may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Sutherland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2002 | 93 | |
| 2 | 2008 | 93 | |
| 3 | 2009 | 73 | |
| 4 | 2005 | 58 | |
| 5 | 2012 | 58 | |
| 6 | 2013 | 51 | |
| 7 | 2006 | 49 | |
| 8 | 2000 | 43 | |
| 9 | 2002 | 43 | |
| 10 | 2006 | 38 | |
| 11 | 2012 | 36 | |
| 12 | 2009 | 35 | |
| 13 | 1998 | 34 | |
| 14 | 2013 | 34 | |
| 15 | 2011 | 31 | |
| 16 | 2000 | 28 | |
| 17 | 1999 | 24 | |
| 18 | 2022 | 23 | |
| 19 | 2009 | 20 | |
| 20 | 1994 | 15 |
About Mark Sutherland
Mark Sutherland is a scholar working on Immunology, Biochemistry, Pharmacology, Toxicology and Molecular Biology, having authored 35 papers that have together received 992 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (11 papers), Eicosanoids and Hypertension Pharmacology (5 papers), Pharmacogenetics and Drug Metabolism (5 papers), Bioactive Compounds and Antitumor Agents (4 papers), Glycosylation and Glycoproteins Research (3 papers), Natural product bioactivities and synthesis (3 papers), RNA Interference and Gene Delivery (2 papers) and Synthesis and pharmacology of benzodiazepine derivatives (2 papers). The work is most often cited by research in Immunology (239 citations), Biochemistry (64 citations), Pharmacology (82 citations), Drug Discovery (2 citations) and Molecular Biology (350 citations). Mark Sutherland has collaborated with scholars based in Germany, United Kingdom and United Arab Emirates. Frequent co-authors include Hendrik Fuchs, Christopher Bachran, Iring Heisler, Diana Bachran, Laurence H. Patterson, Steven D. Shnyder, Matthias F. Melzig, Tankred SCHEWE, R Tauber and Santosh Nigam. Their work appears in journals such as FEBS Letters, PLoS ONE, International Journal of Cancer, Journal of Controlled Release and Life Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.